Loading
Atrial Fibrillation (AF) / Semaglutide 2.4 mg / Standard medical treatment · Phase 4 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 4 randomized controlled trial comparing semaglutide plus lifestyle advice versus standard care prior to first AF catheter ablation in overweight or obese patients. The study is currently recruiting and has not yet reported results. The primary outcome is arrhythmia-free survival at 12 months post-ablation assessed by continuous implantable loop recorder monitoring.
Phase 4, Interventional, Randomized, Parallel, Single masking, Treatment purpose. Atrial Fibrillation (AF), Obesity & Overweight; age from 18 Years. Intervention: Randomized to Semaglutide. Compared with: Standard of care — Active Comparator. n = 200. 1 site: Sweden.
This is a registered Phase 4 randomized controlled trial comparing semaglutide plus lifestyle advice versus standard care prior to first AF catheter ablation in overweight or obese patients. The study is currently recruiting and has not yet reported results. The primary outcome is arrhythmia-free survival at 12 months post-ablation assessed by continuous implantable loop recorder monitoring.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This trial is designed to test whether GLP-1 receptor agonist-induced weight loss before AF ablation reduces arrhythmia recurrence. If positive, it would provide the first RCT evidence that pharmacologic weight management optimizes catheter ablation outcomes in overweight or obese AF patients. Results are not yet available.
This is a registered but ongoing Phase 4 randomized trial with no results reported; it is a study plan, not evidence of efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
This trial is designed to test whether GLP-1 receptor agonist-induced weight loss before AF ablation reduces arrhythmia recurrence. If positive, it would provide the first RCT evidence that pharmacologic weight management optimizes catheter ablation outcomes in overweight or obese AF patients. Results are not yet available.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07275697). This is a study registration, not published results. Lead sponsor: Emma Svennberg. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Atrial Fibrillation (AF), Obesity & Overweight. Interventions: DRUG: Semaglutide 2.4 mg; BEHAVIORAL: Standard medical treatment. Primary outcome measures: Arrhythmia-free survival at 12 months after catheter ablation, excluding the 3-month blanking period, with recurrence defined as any ILR-detected AF, atrial flutter, or atrial tachycardia ≥30 seconds. , 12 months post-ablation. Brief summary: Atrial fibrillation (AF) is the most common heart rhythm disorder and is associated with symptoms, reduced quality of life, heart failure, stroke, and a high risk of recurrence after catheter ablation. Many patients scheduled for their first ablation are overweight or have obesity, which is one of the strongest predictors of AF recurrence. Weight loss and risk-factor management are known to improve the outcome of ablation, but lifestyle changes are often difficult to achieve in routine care. Semaglutide (Wegovy®) is a GLP-1 receptor agonist approved in the EU for weight management. It has been shown to produce substantial and sustained weight loss and to improve metabolic and cardiovascular risk factors. Whether treatment with semaglutide before AF ablation can improve long-term rhythm outcomes has never been tested in a randomized clinical trial. The WAIT-AF study is a randomized, open-label trial with blinded endpoint assessment. The study includes adults with AF who are scheduled for their first catheter ablation and have a BMI ≥30 kg/m², or ≥27 kg/m² with at least one additional cardiovascular risk factor (such as hypertension, diabetes and dyslipidemia). A total of 200 participants will be enrolled. Participants are randomly assigned in a 1:1 ratio to either standard care or semaglutide (plus lifestyle advice) prior to their scheduled ablation. Semaglutide is administered according to the approved EU label with gradual dose escalation. All participants receive an implantable loop recorder (ILR) before ablation to continuously monitor heart rhythm throughout the study. The primary objective is to determine whether semaglutide improves arrhythmia-free survival 12 months after AF ablation. Recurrence is defined as AF, atrial flutter, or atrial tachycardia lasting ≥30 seconds on continuous ILR monitoring, excluding the standard 3-month blanking period. Secondary outcomes include weight loss, changes in blood pressure, AF symptoms, quality of life, AF burden, need for repeat ablation, hospitalizations for cardiovascular causes, and changes in metabolic risk factors. The study also evaluates safety and tolerability of semaglutide in this patient population. The study aims to determine whether targeted weight management with semaglutide before AF ablation can improve long-term rhythm outcomes and overall cardiovascular health. If successful, this strategy may offer a new approach to optimizing treatment and improving the results of catheter ablation for patients with AF and overweight or obesity
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.